Our results validate the MuRF1-hiLUCs rat as a noninvasive, quantitative, and versatile biomarker system that can be applied to both basic research and the development of therapeutics for skeletal muscle atrophy. The gene discussed is TRIM63; the disease is muscular atrophy.